EX-23.3 4 ny20057110x1_ex23-3.htm EXHIBIT 23.3

Exhibit 23.3
Consent of Independent Registered Public Accounting Firm
We consent to the reference to our firm under the caption “Experts” in the Registration Statement (Form S-4) and related proxy statement/prospectus of BioCryst Pharmaceuticals, Inc. and to the incorporation by reference therein of our report dated March 11, 2025, with respect to the consolidated financial statements of Astria Therapeutics, Inc. included in Astria Therapeutics, Inc.’s Annual Report (Form 10-K) for the year ended December 31, 2024, filed with the Securities and Exchange Commission.
/s/ Ernst & Young LLP
Boston, Massachusetts
November 20, 2025